Critical onset of layering in sedimenting suspensions of nanoparticles

We quantitatively study the critical onset of layering in suspensions of nanoparticles in a solvent, where an initially homogeneous suspension, subject to an effective gravity a in a centrifuge, spontaneously forms well-defined layers of constant particle density, so that the density changes in a staircaselike manner along the axis of gravity. This phenomenon is well known; yet, it has never been quantitatively studied under reproducible conditions: therefore, its physical mechanism remained controversial and the role of thermal diffusion in this phenomenon was never explored. We demonstrate that the number of layers forming in the sample exhibits a critical scaling as a function of a; a critical dependence on sample height and transverse temperature gradient is established as well. We reproduce our experiments by theoretical calculations, which attribute the layering to a diffusion-limited convective instability, fully elucidating the physical mechanism of layering.

Magnetic properties of Cd(1 - x)Mn(x)Te/C nanocrystals

Mn doped CdTe nanocrystals coated by carbon (Cd(1 - x)Mn(x)Te/C) were synthesized by a one-step, kinetically controlled solid state reaction under autogenic pressure at elevated temperatures. Electron microscopic analysis confirmed that the 40-52 nm Cd(1 - x)Mn(x)Te core was encapsulated by a 6-9 nm carbon shell. The efficient doping by Mn(2+) in the zinc blende Cd(1 - x)Mn(x)Te lattice, up to an atomic ratio of Mn/Cd of 0.031, was confirmed from electron paramagnetic resonance (EPR) experiments. In the case of higher doping, it is likely that manganese is partially expelled to the nanocrystal surface. All the doped samples exhibit ferromagnetism at room temperature. The lowest doped sample has the highest magnetic moment (1.91 ± 0.02 µ(B)/Mn). The more concentrated samples exhibit weaker ferromagnetic interactions, probably due to an incomplete coupling between carriers in the host CdTe semiconductor and dopant spins.

One-pot fabrication and magnetic studies of Mn-doped TiO(2) nanocrystals with an encapsulating carbon layer

Mn-doped TiO(2) nanocrystals encapsulated in a carbon layer (Ti(1-x)Mn(x)O(2)@C) were synthesized by the one-pot RAPET (reaction under autogenic pressure at elevated temperature) technique. Manganese was doped into the body-centered tetragonal TiO(2) anatase phase to give a Mn:Ti atomic ratio of 1%, 5% and 10%. The surface modification by carbon was achieved in order to make the cubic/tetragonal nanocrystals non-toxic and biocompatible. Electron paramagnetic resonance (EPR) studies revealed a broad resonance (centered at g = 1.9977 due to the interacting spins in the oxide matrix) with increased dopant concentration and the resonance due to carbon. Manganese is mainly present as +II or +III oxidation states. The magnetic behavior was found to be very dependent on the manganese concentration with a ferromagnetic behavior of the 1% doped sample due to the coupling between carriers and manganese spins. A predominant paramagnetic behavior was observed for the higher Mn-doped samples. This study opens up a new dimension for the carbon encapsulation of room-temperature ferromagnetic diluted magnetic semiconductor (DMS) nanomaterials.

Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias

Tissue factor pathway inhibitor (TFPI), a kunitztype inhibitor of the extrinsic coagulation pathway, factor VII coagulant (FVIIc), FVIIa, and the fibrinolytic factors plasminogen activator inhibitor-1 (PA1-1) and tissue plasminogen activator (TPA) have been studied in various hyperlipidemias. Compared with a normal lipidic group, mean TFPI activity was 70% higher (P < .001) and 36% higher (P < .001) in type IIa and IIb hyperlipidemias, respectively, and was lower by 13% in type IV hyperlipidemia (P = .05). TFPI was correlated with LDL cholesterol (P < .001), total cholesterol (P < .001), HDL cholesterol (P < .01), apolipoproteins (apo) AI (P < .001) and B (P < .001) and lipoprotein a (P < .01). TFPI was negatively correlated with the triglyceride level (P < .05); the correlation was dependent on LDL cholesterol and HDL cholesterol levels, which were decreased in type IV hyperlipidemia. FVIIc activity (P < .001) was increased by 30% in both type IV and type IIb hyperlipidemia and was correlated with triglyceride levels. FVIIa was not significantly increased in any group compared with control group. FVIIc was correlated with triglyceride level (P < .001), while FVIIa was not. Interestingly, FVIIa was correlated with FVIIc (r = .5, P < .001) in the control group as well as in the hyperlipidemic groups (r = .32, P < .01). These results favor the hypothesis that higher FVIIc concentrations in hyperlipidemic patients are likely due to enhancement of synthesis of FVII and that a part of this FVII circulates in an activated chemical form. Compared with the control group, PAI-1 activity was twofold higher (P < .08) in type IIa hyperlipidemia, threefold higher (P < .001) in type IIb hyperlipidemia, and fourfold higher in type IV hyperlipidemia (P < .001). PAI-1 activity correlated with triglyceride levels (P < .001), apoB levels (P < .001) and total cholesterol levels (P < .05). These correlations were dependent on apoB and probably reflect the correlation between PAI-1 and VLDL. In contrast, TPA level was normal in the different hyperlipidemias. No correlation was found between TFPI, FVIIc, and PAI-1. Variation of TFPI activity appears to be related to the variations of its main lipoprotein carriers: LDL, HDL, and Lp (a). The association in hypertriglycemic patients of hypercoagulability (increased FVIIc and decreased TFPI) and hypofibrinolysis (increased PAI-1) may explain thrombosis predisposition of some of these patients. However, it would be interesting to study the increased levels of endothelium-derived TFPI in plasma induced by the injection of heparin.

Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity

Several studies have suggested a dose-response relation between the oestrogen content of oral contraceptive (OC) and the risk of both venous thrombosis and arterial disease, when oestrogen doses were higher than 50 micrograms. However, there is no clear epidemiological evidence for a decrease in thrombotic risk with formulations containing less than 50 micrograms oestrogen. Therefore, we investigated haemostatic variables in users of OC containing either 30 micrograms (35 women) or 50 micrograms (29 women) ethinyl estradiol as compared with non users (64 women) matched for age and smoking status. Mean values of antithrombin activity were significantly lower in 30 micrograms or 50 micrograms oestrogen users than in non users (96% and 98% vs 105%, respectively, p < 0.001), but they were not significantly different between the two groups of OC users. There was a significant increase in mean values of factor VII antigen in women taking either 30 micrograms or 50 micrograms oestrogen as compared with non users (96% and 101% vs 85%, respectively, p < 0.005). Although the difference between both groups of OC users was not significant, a positive linear trend in factor VII levels was observed within the 0-50 micrograms oestrogen range (p < 0.001). Mean levels of fibrinogen were slightly higher in 30 micrograms or 50 micrograms oestrogen users than in non users (2.71, 2.66 g/l vs 2.55 g/l, respectively), but there was no significant difference between the three groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits

Tissue Factor Pathway Inhibitor (TFPI), is known, to be released in plasma after injection of intravenous or subcutaneous injection of heparin or low molecular weight heparin (1,2). Addition of protamine or polybrene in plasma can neutralize anticoagulant effects of heparin in vitro but not completely ex vivo in patients treated with heparin (3). It was believed for many years that this post-heparin anticoagulant effect was due to another activity released by heparin. More recently it has been shown that post-heparin anticoagulant effect could be inhibited by anti-TFPI antibodies (4). Since we have shown in a previous work (5), that in healthy volunteers, pharmacokinetics of TFPI were more closely related to anti IIa activity than anti Xa activity we hypothesized that fragments with anti-IIa activity may be required for this release, possibly from vascular wall. In order to determine if a very low molecular weight glycosaminoglycan can release TFPI in plasma, in the present study, we compared plasma TFPI amidolytic activity after intravenous injection in rabbits of pentasaccharide (PS), a synthetic fragment of very low molecular weight and with a strong and exclusive anti Xa activity, and unfractionated heparin (UFH).

Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor

In a randomized crossover study twelve healthy male volunteers (23.5 +/- of 4.8 years, 73.0 +/- 6.4 kg, 180.8 +/- 5.7 cm) received one subcutaneous injection of either enoxaparin (EN) at 40 mg or 1 mg kg-1, or unfractionated heparin (UH) at 5,000 IU at one week intervals. Area under curves (AUC) of Anti-Xa and Anti-IIa activities correlated with EN dose. The relative effectiveness of EN versus UH 5,000 U as assessed by AUC ratio (EN/UH) was 7 and 15 for Anti-Xa activity, 1.3 and 3.1 for Anti-IIa activity after sc injection of EN 40 mg (4,000 Anti-Xa IU and 1,200 Anti-IIa U) and 1 mg kg-1 (7,300 +/- 640 Anti-Xa IU and 2,190 +/- 290 Anti-IIa IU) respectively. In volunteers receiving EN, a dose dependent inhibition of thrombin generation rate in platelet depleted plasma (PDP), measured with a new and simple chromogenic thrombin generation assay, was observed when compared with baseline values. Similarly, intrinsic prothrombin activation in whole blood, evidenced by measuring residual factor II in serum 2 hours after clotting (prothrombin consumption test: PC), was inhibited in a dose dependent manner. In UH treated volunteers, although the inhibition of thrombin generation rate in PDP was similar to that observed with EN 40 mg, prothrombin consumption in whole blood was not significantly modified. Tissue factor pathway inhibitor (TFPI) activity release was increased similarly for UH and EN 40 (1.4 fold increase above baseline values) and 1.9 fold for the higher dose of EN. The discrepancy between prothrombin consumption in whole blood and inhibition of thrombin generation rate in PDP in the UH and not in the EN group strongly suggests that UH and not EN is influenced by the presence of a platelet component. This could be formed during thrombin induced platelet activation. Platelet factor 4 is a possible candidate. Another hypothesis involves the role of TFPI-UH complex anticoagulant activity which might be inhibited more during whole blood coagulation than the TFPI-EN complex.